Philips has introduced a new generation of wearable biosensors for early detection of deterioration of the patient’s clinical condition, including clinical surveillance for COVID-19.
The Philips BX100 biosensor is designed to enable a new approach to measuring the vital parameters of patients moving from intensive care units to lower intensity care departments. The biosensor is a 96mm long and 61mm wide disposable patch weighing only 10 grams that can be worn for 5 days. The BX100 can be connected wirelessly with a hub to monitor multiple patients in multiple rooms.
The device, which requires no cleaning or recharging, adheres discreetly to the chest to measure and transmit respiratory rate and heart rate every minute – the two main predictors of clinical deterioration – as well as contextual parameters such as posture, activity level and gait.
OLVG, one of the leading hospitals in the Netherlands, is remotely monitoring patients diagnosed or suspected with COVID-19 and who do not need ventilation. These patients, who are isolated in special rooms, are monitored with Philips’ clinical deterioration detection solution which includes intelligent analysis software (IntelliVue GuardianSoftware) for early warning, monitors (EarlyVue VS30) and Philips Biosensor BX100 wearable sensors.
“With the help of this new biosensor, we can monitor patients continuously and remotely, which is particularly important in the COVID-19 wards,” said Florian van der Hunnik, head of nursing information and team leader of the COVID-19 ward of the OLVG hospital in Amsterdam. “Since we cannot enter and exit patient rooms without protective equipment, we welcome this innovation as it helps to improve the way we can do our job.”
Digital-health 